Theranautilus Secures $1.2 Million in Seed Funding to Revolutionize Dental Healthcare with Nanorobotics
We are excited to announce that
has successfully advised Theranautilus, a pioneering deep-tech firm specializing in nanorobotics solutions for healthcare, in securing $1.2 million in seed funding.
This funding round was led by pi Ventures and included participation from Golden Sparrow Ventures, along with notable angel investors such as Abhishek Goyal, founder and CEO of Traxcn, and Lalit Keshre, CEO of Groww.
As Shanmukh Srinivas, CEO and Co-Founder at Theranautilus, aptly puts it:
“Aritra Partners has been an invaluable partner to Theranautilus since the inception of our seed fund journey. Their seasoned team provided exceptional support throughout the process, offering invaluable guidance in legal, financial, and business negotiations. We extend our sincere gratitude to Abhishek, Pooja, and Sadashiva for their unwavering dedication and expertise. We look forward to continuing our fruitful collaboration with Aritra Partners in the years to come.”
The funds raised will be instrumental in commercializing Theranautilus’s innovative nanorobotics-based medical devices, initially targeting dental care applications. This strategic investment will also support the development of a robust go-to-market strategy and expand the company’s technological advancements beyond dental applications.
Founded in 2020 by esteemed researchers Ambarish Ghosh, Debayan Dasgupta, and Peddi Shanmukh Srinivas at the Indian Institute of Science (IISc), Theranautilus is poised to transform dental healthcare. Their technology addresses significant challenges such as dental hypersensitivity, which affects over 2 billion people globally and represents a substantial market opportunity valued at approximately $6 billion.
Theranautilus’s approach utilizes precision-manufactured nanorobots to deliver biocompatible materials directly to targeted locations within dental tissues. These materials can be externally triggered to form bio-mimetic structures that repair damaged tissues, offering long-term solutions for patients.
With international patents backing its innovative technology, Theranautilus aims to develop precision theranostics-based interventions not only for dental issues but also for managing cancer therapy and other diseases.
This funding marks a significant step towards revolutionizing healthcare through advanced nanotechnology.
